XML 115 R21.htm IDEA: XBRL DOCUMENT v3.20.1
Income Taxes
12 Months Ended
Dec. 31, 2019
Income Tax Disclosure [Abstract]  
Income Taxes

15.

Income Taxes

 

 

 

Year Ended December 31,

 

 

 

2019

 

 

2018

 

 

2017

 

Income Before Taxes:

 

 

 

 

 

 

 

 

 

 

 

 

Domestic

 

$

(54,789

)

 

$

(6,597

)

 

$

(45,377

)

Foreign

 

 

—

 

 

 

—

 

 

 

—

 

Total income before income taxes

 

$

(54,789

)

 

$

(6,597

)

 

$

(45,377

)

 

 

Income Taxes

During the years ended December 31, 2019, 2018, and 2017, the Company recorded no income tax benefits for the net losses incurred or for the research and development tax credits generated in each year due to its uncertainty of realizing a benefit from those items.

A reconciliation of the U.S. federal statutory income tax rate to the Company’s effective income tax rate is as follows:

 

 

 

Year Ended December 31,

 

 

 

2019

 

 

2018

 

 

2017

 

Federal statutory income tax rate

 

 

(21.0

)%

 

 

(21.0

)%

 

 

(35.0

)%

State taxes, net of federal benefit

 

 

(6.2

)

 

 

(6.2

)

 

 

(5.2

)

Permanent differences

 

 

0.0

 

 

 

1.1

 

 

 

0.3

 

Stock-based compensation

 

 

1.0

 

 

 

5.2

 

 

 

2.6

 

Research and development tax credits

 

 

(7.9

)

 

 

(13.7

)

 

 

(0.9

)

Increase in deferred tax asset valuation allowance

 

 

33.7

 

 

 

34.5

 

 

 

18.6

 

Other

 

 

0.4

 

 

 

0.1

 

 

 

—

 

Change in statutory tax rate

 

 

—

 

 

 

—

 

 

 

19.6

 

Effective income tax rate

 

 

—

%

 

 

—

%

 

 

—

%

 

Significant components of Surface Oncology’s deferred tax assets and liabilities as of December 31, 2019 and 2018 are as follows:

 

 

 

December 31,

 

 

 

2019

 

 

2018

 

Deferred tax assets:

 

 

 

 

 

 

 

 

Net operating loss carryforwards

 

$

19,629

 

 

$

5,240

 

Research and development tax credit carryforwards

 

 

6,234

 

 

 

1,945

 

Deferred revenue

 

 

10,543

 

 

 

14,740

 

Deferred rent

 

 

—

 

 

 

1,376

 

Intangible assets

 

 

430

 

 

 

791

 

Accrued expenses

 

 

843

 

 

 

687

 

Stock-based compensation

 

 

2,414

 

 

 

1,468

 

Lease liability

 

 

5,445

 

 

 

—

 

Other

 

 

23

 

 

 

73

 

Total deferred tax assets

 

 

45,561

 

 

 

26,320

 

Valuation allowance

 

 

(36,535

)

 

 

(18,602

)

Deferred tax assets

 

 

9,026

 

 

 

7,718

 

Deferred tax liabilities:

 

 

 

 

 

 

 

 

Right-of-use asset

 

 

(4,059

)

 

 

—

 

Depreciation

 

 

(1,281

)

 

 

(1,629

)

Deferred revenue tax accounting method change

 

 

(3,045

)

 

 

(6,089

)

Beneficial conversion feature on convertible note payable

 

 

(559

)

 

 

—

 

Other

 

 

(82

)

 

 

—

 

Total deferred tax liabilities

 

 

(9,026

)

 

 

(7,718

)

Net deferred tax assets

 

$

—

 

 

$

—

 

 

As of December 31, 2019, the Company had federal and state net operating loss carryforwards of $71,495 and $73,021, respectively, and federal and state research and development tax credit carryforwards of $4,501 and $2,025, respectively, available to reduce future income tax liabilities. The federal and state net operating loss carryforwards each begin to expire in 2034. The federal and state research and development tax credit carryforwards begin to expire in 2034 and 2030, respectively.

Utilization of the Company's net operating loss ("NOL") carryforwards and research and development ("R&D") credit carryforwards may be subject to a substantial annual limitation due to ownership change limitations that have occurred previously or that could occur in the future in accordance with Section 382 of the Internal Revenue Code of 1986 ("Section 382") as well as similar state provisions. These ownership changes may limit the amount of NOL and R&D credit carryforwards that can be utilized annually to offset future taxable income and taxes, respectively. In general, an ownership change as defined by Section 382 results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50% over a three-year period. Since its formation, the Company has raised capital through the issuance of capital stock on several occasions. These financings, combined with the purchasing shareholders' subsequent disposition of those shares, could result in a change of control as defined by Section 382. The Company conducted an analysis under Section 382 to determine if historical changes in ownership through December 31, 2018 would limit or otherwise restrict its ability to utilize its NOL and R&D credit carryforwards. As a result of this analysis, the Company does not believe there are any significant limitations on its ability to utilize these carryforwards.  However, future changes in ownership occurring after December 31, 2018 could affect the limitation in future years, and any limitation may result in expiration of a portion of the NOL or R&D credit carryforwards before utilization.

As required by the provisions of ASC 740, management considers whether it is more likely than not that some portion or all of the net deferred tax assets will not be realized. Based upon the level of historical U.S. losses, management has determined that it is “more-likely-than-not” that the Company will not utilize the benefits of federal and state deferred tax assets for financial reporting purposes and, as a result, a full valuation allowance has been established at December 31, 2019 and 2018. The valuation allowance decrease primarily relates to the decrease in deferred revenue, and were as follows:

 

 

 

Year Ended December 31,

 

 

 

2019

 

 

2018

 

 

2017

 

Valuation allowance at beginning of year

 

$

(18,602

)

 

$

(19,956

)

 

$

(11,531

)

Increases recorded to income tax provision

 

 

(17,933

)

 

 

(5,644

)

 

 

(17,302

)

Decreases recorded as a benefit to income

   tax provision

 

 

—

 

 

 

6,998

 

 

 

8,877

 

Valuation allowance at end of year

 

$

(36,535

)

 

$

(18,602

)

 

$

(19,956

)

 

The Company had no unrecognized tax benefits or related interest and penalties accrued for the years ended December 31, 2019 and 2018. The Company will recognize interest and penalties related to uncertain tax positions in income tax expense.

The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. The Company is currently under examination by the Internal Revenue Service ("IRS") for the period ended December 31, 2016. The Company's tax years are still open under statute from 2016 to present. All years may be examined to the extent the tax credit or net operating loss carryforwards are used in future periods.